Zobrazeno 1 - 10 of 56 pro vyhledávání: '"Salcedo MT"'
1
Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study
Autor: Juan Bañares, Ramiro Manzano-Nuñez, Alba Prió, Jesús Rivera-Esteban, Laura Camps-Relats, Ana Villarejo, Lourdes Ruiz-Ortega, Mònica Pons, Andreea Ciudin, María Teresa Salcedo, Víctor Vargas, Joan Genescà, Juan M. Pericàs
Publikováno v: Scientia
Hepatic outcomes; Infections; Sodium-glucose co-transporter-2 inhibitors Resultados hepáticos; Infecciones; Inhibidores del cotransportador de sodio-glucosa-2 Resultats hepàtics; Infeccions; Inhibidors del cotransportador de sodi-glucosa-2 Introduc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4fcb47832371617bd42a3bb5e94ef0a
Zobrazit plný text záznamu
2
Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report
Autor: Jesús Rivera-Esteban, Aurora Barberá, Maria Teresa Salcedo, Maria Martell, Joan Genescà, Juan M. Pericàs
Publikováno v: Scientia
Esteatosi hepàtica; Hipertensió portal Liver steatosis; Portal hypertension Esteatosis hepática; Hipertensión portal No financial support was received for data analysis or writing assistance. JRE is a PhD student at Universitat Autònoma de Barce
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::758a7d50cc5fa323d2579c587589a4d5
https://pubmed.ncbi.nlm.nih.gov/36478872
Zobrazit plný text záznamu
3
A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo
Autor: Iris Pinheiro, Aurora Barberá, Imma Raurell, Federico Estrella, Marcel de Leeuw, Selin Bolca, Davide Gottardi, Nigel Horscroft, Sam Possemiers, María Teresa Salcedo, Joan Genescà, María Martell, Salvador Augustin
Publikováno v: Scientia
Biomedicines; Volume 10; Issue 5; Pages: 1191
Bacterial consortium; Gut microbiome; Portal hypertension Consorcio bacteriano; Microbioma intestinal; Hipertensión portal Consorci bacterià; Microbioma intestinal; Hipertensió portal The gut microbiome has a recognized role in Non-alcoholic fatty
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dfcce309521bdc0330380dec455bcac
https://hdl.handle.net/11585/909235
Zobrazit plný text záznamu
4
Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management
Autor: Mónica Higuera, Elena Vargas-Accarino, María Torrens, Josep Gregori, María Teresa Salcedo, Joan Martínez-Campreciós, Gloria Torres, María Bermúdez-Ramos, Itxarone Bilbao, Mercedes Guerrero-Murillo, Xavier Serres-Créixams, Xavier Merino, Francisco Rodríguez-Frías, Josep Quer, Beatriz Mínguez
Publikováno v: Scientia
Cancers; Volume 14; Issue 16; Pages: 3875
Biomarkers; cfDNA; Liquid biopsy Biomarcadores; cfDNA; Biopsia líquida Biomarcadors; cfDNA; Biòpsia líquida Background: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6255f1e1643dccdda3faf01e664f028d
https://doi.org/10.3390/cancers14163875
Zobrazit plný text záznamu
5
Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH
Autor: Joan Genescà, Salvador Augustin, Mar Gil, María Martell, Imma Raurell, Diana Hide, Aurora Barberá, Federico Estrella, María Teresa Salcedo, Miren Bravo
Publikováno v: Disease Models & Mechanisms
article-version (VoR) Version of Record
Disease Models & Mechanisms, Vol 14, Iss 5 (2021)
Scientia
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca1c507db803d0ab75718846650967ac
https://doi.org/10.1242/dmm.048884
Zobrazit plný text záznamu
6
ARMCX3 Mediates Susceptibility to Hepatic Tumorigenesis Promoted by Dietary Lipotoxicity
Autor: José María Balibrea, Roman Serrat, Carmen Berasain, Monica Higuera, Aleix Gavaldà-Navarro, Eduardo Soriano, Matías A. Avila, Iker Uriarte, María Teresa Salcedo, Francesc Villarroya, Eva Santamaría, Beatriz Minguez, Yasmina Manso, Serena Mirra, Ferran Burgaya
Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Cancers
Scientia
Volume 13
Issue 5
Cancers, Vol 13, Iss 1110, p 1110 (2021)
Simple Summary An excess fat in the liver enhances the susceptibility to hepatic cancer. We found that Armcx3, a protein only known to date to play a role in neural development, is strongly increased in mouse liver in response to lipid availability a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b0494b5535ce05925fea4f831fd988
https://ddd.uab.cat/record/255426
Zobrazit plný text záznamu
7
Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC)
Autor: Jazmine Arévalo, David Lorente, Anna Meseguer, Enrique Trilla, María Teresa Salcedo, Juan Morote
Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Scientific Reports
Biomarcadors tumorals; Càncer urològic Biomarcadores tumorales; Cáncer urológico Tumour biomarkers; Urological cancer Clear cell renal cell carcinoma (ccRCC) is the most frequent and aggressive subtype of renal carcinoma. So far, the basis of its
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b0f48e9df6944c1d45b9526a756822
https://ddd.uab.cat/record/255384
Zobrazit plný text záznamu
8
Akademický článek
Enhanced Artificial Intelligence Methods for Liver Steatosis Assessment Using Machine Learning and Color Image Processing: Liver Color Project.
Autor: Gómez-Gavara C; Barcelona Autonoma University, Universitat Autónoma de Barcelona, Barcelona, Spain.; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain., Bilbao I; Barcelona Autonoma University, Universitat Autónoma de Barcelona, Barcelona, Spain.; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain., Piella G; Barcelona MedTech, Universidad Pompeu Fabra, Barcelona, Spain., Vazquez-Corral J; Computer Vision Center and Computer Sciences Department, Universitat Autònoma de Barcelona, Barcelona, Spain., Benet-Cugat B; Barcelona MedTech, Universidad Pompeu Fabra, Barcelona, Spain., Pando E; Barcelona Autonoma University, Universitat Autónoma de Barcelona, Barcelona, Spain.; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain., Molino JA; Servicio de Cirugía Pediátrica, Hospital Universitari Vall d´Hebron, Barcelona, Spain., Salcedo MT; Servicio de Anatomía Patológica, Hospital Universitari Vall d´Hebron, Barcelona, Spain., Dalmau M; Barcelona Autonoma University, Universitat Autónoma de Barcelona, Barcelona, Spain.; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain., Vidal L; Barcelona Autonoma University, Universitat Autónoma de Barcelona, Barcelona, Spain.; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain., Esono D; Barcelona MedTech, Universidad Pompeu Fabra, Barcelona, Spain., Cordobés MÁ; Barcelona MedTech, Universidad Pompeu Fabra, Barcelona, Spain., Bilbao Á; Barcelona Autonoma University, Universitat Autónoma de Barcelona, Barcelona, Spain., Prats J; Barcelona MedTech, Universidad Pompeu Fabra, Barcelona, Spain., Moya M; Barcelona MedTech, Universidad Pompeu Fabra, Barcelona, Spain., Dopazo C; Barcelona Autonoma University, Universitat Autónoma de Barcelona, Barcelona, Spain.; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain., Mazo C; Coordinación de Trasplantes, Hospital Universitari Vall d´Hebron, Barcelona, Spain., Caralt M; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain., Hidalgo E; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain., Charco R; Servicio de Cirugía HBP y Trasplante, Hospital Universitari Vall d´Hebron, Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain.
Publikováno v: Clinical transplantation [Clin Transplant] 2024 Oct; Vol. 38 (10), pp. e15465.
Zobrazit plný text záznamu
9
Akademický článek
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Autor: Riveiro-Barciela M; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.; Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; CIBERehd, Instituto Carlos III, Barcelona, Spain., Barreira-Díaz A; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.; Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Salcedo MT; Human Pathology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Callejo-Pérez A; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Muñoz-Couselo E; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Iranzo P; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Ortiz-Velez C; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Cedrés S; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Díaz-Mejía N; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Ruiz-Cobo JC; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.; Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Morales R; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Aguilar-Company J; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Zamora E; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Oliveira M; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Sanz-Martínez MT; Immunology Division, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Translational Immunology Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.; Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB), Barcelona, Spain., Viladomiu L; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., Martínez-Gallo M; Immunology Division, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Translational Immunology Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.; Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB), Barcelona, Spain., Felip E; Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Buti M; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.; Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; CIBERehd, Instituto Carlos III, Barcelona, Spain.
Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Apr; Vol. 59 (7), pp. 865-876. Date of Electronic Publication: 2024 Feb 07.
Zobrazit plný text záznamu
10
Akademický článek
Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells.
Autor: Gil M; Liver Disease Group, Liver Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Universitat Autonòma de Barcelona (UAB), 08035 Barcelona, Spain., Khouri L; Institut of Chemistry, Casali Center for Applied Chemistry, The Center for Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Jerusalem 91904, Israel., Raurell I; Liver Disease Group, Liver Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Universitat Autonòma de Barcelona (UAB), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Rafael D; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Andrade F; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Departament de Farmàcia i Tecnologia Farmacèutica i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), 08007 Barcelona, Spain., Abasolo I; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Clinical Biochemistry Service, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035e Barcelona, Spain., Schwartz S Jr; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Clinical Biochemistry Service, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035e Barcelona, Spain., Martínez-Gómez M; Liver Disease Group, Liver Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Universitat Autonòma de Barcelona (UAB), 08035 Barcelona, Spain., Salcedo MT; Pathology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Pericàs JM; Liver Disease Group, Liver Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Universitat Autonòma de Barcelona (UAB), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Hide D; Liver Disease Group, Liver Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Universitat Autonòma de Barcelona (UAB), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Wei M; Cellvax, SAS Villejuif Bio Park, 93230 Villejuif, France., Metanis N; Institut of Chemistry, Casali Center for Applied Chemistry, The Center for Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Jerusalem 91904, Israel., Genescà J; Liver Disease Group, Liver Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Universitat Autonòma de Barcelona (UAB), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Martell M; Liver Disease Group, Liver Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, Universitat Autonòma de Barcelona (UAB), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto De Salud Carlos III, 08035 Barcelona, Spain.
Publikováno v: Pharmaceutics [Pharmaceutics] 2023 Oct 14; Vol. 15 (10). Date of Electronic Publication: 2023 Oct 14.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje